Episodios

  • Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease

    Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease
    May 1 2025
    In this episode, we are joined by entrepreneur and television personality, Barbara Corcoran. While many know Barbara for her business acumen and dynamic presence on Shark Tank, fewer may know the deeply personal and powerful story she shares today—her nine-year journey as a caregiver for her mother, who lived with Alzheimer disease. In this heartfelt conversation, Barbara opens up about the early signs her family overlooked, the emotional toll of watching her mother's personality shift, and the pivotal moment that changed their approach to caregiving. From practical strategies to navigate agitation in Alzheimer disease, to profound lessons in empathy, patience, and family dynamics, Barbara’s story offers inspiration and wisdom for caregivers and physicians. For more information, please visit www.RecognizeAlzheimersAgitation.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    18 m
  • Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test

    Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test
    Mar 21 2025
    Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    21 m
  • Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group

    Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group
    Feb 25 2025
    Nicolas Villain, MD, PhD, Associate Professor of Neurology, Sorbonne University, Paris, France, discusses the International Working Group’s updated diagnostic criteria for the diagnosis and staging of Alzheimer disease, which offer an alternative definitional view of AD as a clinical-biologic construct. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    12 m
  • Blarcamesine: An Investigational Oral Drug for Alzheimer Disease

    Blarcamesine: An Investigational Oral Drug for Alzheimer Disease
    Jan 25 2025
    Timo Grimmer, MD, Associate Professor of Psychiatry and Psychotherapy and Head of the Centre for Cognitive Disorders at the Technical University of Munich, Germany, discusses the experimental oral small molecule drug blarcamesine, which is under investigation as a potential treatment for Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    16 m
  • The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers

    The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers
    Dec 19 2024
    Sarena Ho, Health Insurance Specialist at the CMS Innovation Center, provides an overview on the Guiding an Improved Dementia Experience (GUIDE) Model, which helps physicians provide coordinated care to support patients with dementia and their caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    11 m
  • The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

    The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease
    Nov 19 2024
    Gary E. Gibson, PhD, Professor of Neurosciences, Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, details his research related to metabolic changes associated with Alzheimer disease and a clinical trial studying the effects of benfotiamine therapy on cognitive and other outcomes. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    16 m
  • BrainCheck as a Digital Cognitive Assessment Tool

    BrainCheck as a Digital Cognitive Assessment Tool
    Nov 8 2024
    Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    7 m
  • Kramer, Van Dyck

    Kramer, Van Dyck
    Sep 27 2024
    Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
    12 m